{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,6,4]],"date-time":"2025-06-04T04:10:29Z","timestamp":1749010229606,"version":"3.41.0"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,6,3]],"date-time":"2025-06-03T00:00:00Z","timestamp":1748908800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,6,3]],"date-time":"2025-06-03T00:00:00Z","timestamp":1748908800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>The pathological classification of nonspecific interstitial pneumonia (NSIP) with organizing pneumonia (OP) overlap (NSIP\/OP overlap) remains complex due to overlapping pathological features, and its heterogeneity is not well understood. We retrospectively analysed adult patients with interstitial lung disease (ILD) diagnosed with NSIP\/OP overlap via surgical lung biopsy. Patients were pathologically subclustered using an unbiased clustering method, and clinical, radiological, and prognostic differences were examined. Among 38 patients, two pathological clusters were identified: Cluster 1, characterized by fibrotic changes with mild inflammation, and Cluster 2, exhibiting intense inflammation with fibrosis. While both clusters initially responded well to treatment, Cluster 2 demonstrated progressive ILD deterioration and a higher frequency of pulmonary fibrosis. Cluster 2 was also associated with hypoxia, reduced pulmonary function, elevated erythrocyte sedimentation rate, and greater consolidation on chest computed tomography. Based on these findings, we have identified NSIP\/OP overlap is a heterogeneous and progressive disease and pathological findings at diagnosis significantly influence both initial ILD severity and long-term prognosis. Our findings highlight the need for tailored long-term management strategies based on early histopathological evaluation.<\/jats:p>","DOI":"10.1038\/s41598-025-04259-y","type":"journal-article","created":{"date-parts":[[2025,6,3]],"date-time":"2025-06-03T09:52:15Z","timestamp":1748944335000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Quantitative analysis of pathological findings identified clinical heterogeneity in nonspecific interstitial pneumonia with organising pneumonia overlap"],"prefix":"10.1038","volume":"15","author":[{"given":"Masato","family":"Asaoka","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hideya","family":"Kitamura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tae","family":"Iwasawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koji","family":"Okudela","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tamiko","family":"Takemura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takashi","family":"Ogura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,6,3]]},"reference":[{"issue":"9","key":"4259_CR1","first-page":"11230","volume":"8","author":"XR Li","year":"2015","unstructured":"Li, X. R., Peng, S. C. & Wei, L. Q. Nonspecific interstitial pneumonia overlaps organizing pneumonia in lung-dominant connective tissue disease. Int. J. Clin. Exp. Pathol. 8(9), 11230\u201311235 (2015).","journal-title":"Int. J. Clin. Exp. Pathol."},{"key":"4259_CR2","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.rmed.2016.10.019","volume":"121","author":"H Hozumi","year":"2016","unstructured":"Hozumi, H. et al. Comprehensive assessment of myositis-specific autoantibodies in polymyositis\/dermatomyositis-associated interstitial lung disease. Respir. Med. 121, 91\u201399 (2016).","journal-title":"Respir. Med."},{"issue":"2","key":"4259_CR3","doi-asserted-by":"publisher","first-page":"311","DOI":"10.21037\/jtd-22-1219","volume":"15","author":"HM Nurmi","year":"2023","unstructured":"Nurmi, H. M. et al. Inflammatory myositis-associated interstitial lung disease can be distinguished from that associated with other connective tissue diseases. J. Thorac. Dis. 15(2), 311\u2013322 (2023).","journal-title":"J. Thorac. Dis."},{"issue":"11","key":"4259_CR4","doi-asserted-by":"publisher","first-page":"2981","DOI":"10.1007\/s10067-018-4289-6","volume":"37","author":"X Dong","year":"2018","unstructured":"Dong, X. et al. A retrospective analysis of distinguishing features of chest HRCT and clinical manifestation in primary Sj\u00f6gren\u2019s syndrome-related interstitial lung disease in a Chinese population. Clin. Rheumatol. 37(11), 2981\u20132988 (2018).","journal-title":"Clin. Rheumatol."},{"issue":"10","key":"4259_CR5","doi-asserted-by":"publisher","first-page":"5924","DOI":"10.21037\/jtd.2018.09.42","volume":"10","author":"H Yamakawa","year":"2018","unstructured":"Yamakawa, H. et al. Interstitial lung disease associated with anti-citrullinated peptide\/protein antibody-positive anti-synthetase syndrome. J. Thorac. Dis. 10(10), 5924\u20135931 (2018).","journal-title":"J. Thorac. Dis."},{"issue":"6","key":"4259_CR6","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1111\/j.1365-2559.2004.01896.x","volume":"44","author":"D Tansey","year":"2004","unstructured":"Tansey, D. et al. Variations in histological patterns of interstitial pneumonia between connective tissue disorders and their relationship to prognosis. Histopathology 44(6), 585\u2013596 (2004).","journal-title":"Histopathology"},{"key":"4259_CR7","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.rmed.2016.07.009","volume":"118","author":"AC Zamora","year":"2016","unstructured":"Zamora, A. C. et al. Clinical features and outcomes of interstitial lung disease in anti-Jo-1 positive antisynthetase syndrome. Respir. Med. 118, 39\u201345 (2016).","journal-title":"Respir. Med."},{"key":"4259_CR8","doi-asserted-by":"publisher","first-page":"1096203","DOI":"10.3389\/fmed.2022.1096203","volume":"9","author":"T Karampitsakos","year":"2023","unstructured":"Karampitsakos, T. et al. Clinical features and outcomes of patients with myositis associated-interstitial lung disease. Front. Med. (Lausanne). 9, 1096203 (2023).","journal-title":"Front. Med. (Lausanne)."},{"key":"4259_CR9","doi-asserted-by":"publisher","first-page":"1392659","DOI":"10.3389\/fmed.2024.1392659","volume":"11","author":"V Tzilas","year":"2024","unstructured":"Tzilas, V. et al. Presenting clinical and imaging features of patients with clinically amyopathic interstitial lung disease associated with myositis-specific autoantibodies. Front. Med. (Lausanne). 11, 1392659 (2024).","journal-title":"Front. Med. (Lausanne)."},{"issue":"3","key":"4259_CR10","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1016\/j.resinv.2019.12.003","volume":"58","author":"N Aiko","year":"2020","unstructured":"Aiko, N. et al. Clinical, radiological, and pathological features of anti-asparaginyl tRNA synthetase antibody-related interstitial lung disease. Respir. Investig. 58(3), 196\u2013203 (2020).","journal-title":"Respir. Investig."},{"issue":"3","key":"4259_CR11","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1159\/000488358","volume":"96","author":"H Yamakawa","year":"2018","unstructured":"Yamakawa, H. et al. Predictive factors for the long-term deterioration of pulmonary function in interstitial lung disease associated with anti-aminoacyl-tRNA synthetase antibodies. Respiration 96(3), 210\u2013221 (2018).","journal-title":"Respiration"},{"issue":"12","key":"4259_CR12","doi-asserted-by":"publisher","first-page":"1338","DOI":"10.1164\/rccm.200611-1685OC","volume":"177","author":"WD Travis","year":"2008","unstructured":"Travis, W. D. et al. Idiopathic nonspecific interstitial pneumonia: report of an American Thoracic Society project. Am. J. Respir. Crit. Care Med. 177(12), 1338\u20131347 (2008).","journal-title":"Am. J. Respir. Crit. Care Med."},{"issue":"6","key":"4259_CR13","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1164\/rccm.201308-1483ST","volume":"188","author":"WD Travis","year":"2013","unstructured":"Travis, W. D. et al. An official American Thoracic Society\/European Respiratory Society statement: Update of the international multidisciplinary classification of the idiopathic interstitial pneumonias. Am. J. Respir. Crit. Care Med. 188(6), 733\u2013748 (2013).","journal-title":"Am. J. Respir. Crit. Care Med."},{"issue":"4","key":"4259_CR14","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1183\/13993003.00150-2015","volume":"46","author":"A Fischer","year":"2015","unstructured":"Fischer, A. et al. An official European Respiratory Society\/American Thoracic Society research statement: interstitial pneumonia with autoimmune features. Eur. Respir. J. 46(4), 976\u2013987 (2015).","journal-title":"Eur. Respir. J."},{"issue":"11","key":"4259_CR15","doi-asserted-by":"publisher","first-page":"1460","DOI":"10.1016\/j.rmed.2015.09.015","volume":"109","author":"NW Todd","year":"2015","unstructured":"Todd, N. W. et al. Organizing pneumonia\/non-specific interstitial pneumonia overlap is associated with unfavorable lung disease progression. Respir. Med. 109(11), 1460\u20131468 (2015).","journal-title":"Respir. Med."},{"key":"4259_CR16","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmed.2020.106201","volume":"174","author":"N Enomoto","year":"2020","unstructured":"Enomoto, N. et al. Clinical, radiological, and pathological evaluation of \u201cNSIP with OP overlap\u201d pattern compared with NSIP in patients with idiopathic interstitial pneumonias. Respir. Med. 174, 106201 (2020).","journal-title":"Respir. Med."},{"issue":"4","key":"4259_CR17","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1111\/his.12415","volume":"65","author":"M Kambouchner","year":"2014","unstructured":"Kambouchner, M. et al. Prognostic relevance of histological variants in nonspecific interstitial pneumonia. Histopathology 65(4), 549\u2013560 (2014).","journal-title":"Histopathology"},{"issue":"2","key":"4259_CR18","doi-asserted-by":"publisher","DOI":"10.1148\/radiol.232558","volume":"310","author":"AA Bankier","year":"2024","unstructured":"Bankier, A. A. et al. Fleischner Society: glossary of terms for thoracic imaging. Radiology 310(2), e232558 (2024).","journal-title":"Radiology"},{"issue":"9","key":"4259_CR19","doi-asserted-by":"publisher","first-page":"e18","DOI":"10.1164\/rccm.202202-0399ST","volume":"205","author":"G Raghu","year":"2022","unstructured":"Raghu, G. et al. Idiopathic pulmonary fibrosis (an update) and progressive pulmonary fibrosis in adults: An official ATS\/ERS\/JRS\/ALAT clinical practice guideline. Am. J. Respir. Crit. Care Med. 205(9), e18\u2013e47 (2022).","journal-title":"Am. J. Respir. Crit. Care Med."},{"issue":"12","key":"4259_CR20","doi-asserted-by":"publisher","first-page":"3038","DOI":"10.3390\/diagnostics12123038","volume":"12","author":"R Aoki","year":"2022","unstructured":"Aoki, R. et al. Effects of automatic deep-learning-based lung analysis on quantification of interstitial lung disease: correlation with pulmonary function test results and prognosis. Diagnostics (Basel). 12(12), 3038 (2022).","journal-title":"Diagnostics (Basel)."},{"issue":"1","key":"4259_CR21","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1186\/s12890-016-0325-y","volume":"16","author":"H Sasano","year":"2016","unstructured":"Sasano, H. et al. Long-term clinical course of anti-glycyl tRNA synthetase (anti-EJ) antibody-related interstitial lung disease pathologically proven by surgical lung biopsy. BMC Pulm. Med. 16(1), 168 (2016).","journal-title":"BMC Pulm. Med."},{"issue":"6","key":"4259_CR22","doi-asserted-by":"publisher","first-page":"874","DOI":"10.1038\/modpathol.2010.65","volume":"23","author":"SA Yousem","year":"2010","unstructured":"Yousem, S. A. et al. The pulmonary histopathologic manifestations of the anti-Jo-1 tRNA synthetase syndrome. Mod. Pathol. 23(6), 874\u2013880 (2010).","journal-title":"Mod. Pathol."},{"issue":"2","key":"4259_CR23","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1378\/chest.10-0194","volume":"138","author":"A Fischer","year":"2010","unstructured":"Fischer, A. et al. Connective tissue disease-associated interstitial lung disease: a call for clarification. Chest 138(2), 251\u2013256 (2010).","journal-title":"Chest"},{"issue":"5","key":"4259_CR24","doi-asserted-by":"publisher","first-page":"1292","DOI":"10.1378\/chest.10-2662","volume":"140","author":"R Vij","year":"2011","unstructured":"Vij, R., Noth, I. & Strek, M. E. Autoimmune-featured interstitial lung disease: a distinct entity. Chest 140(5), 1292\u20131299 (2011).","journal-title":"Chest"},{"key":"4259_CR25","doi-asserted-by":"crossref","unstructured":"American Thoracic Society; European Respiratory Society. American Thoracic Society\/European Respiratory Society International Multidisciplinary Consensus Classification of the Idiopathic Interstitial Pneumonias. This joint statement of the American Thoracic Society (ATS), and the European Respiratory Society (ERS) was adopted by the ATS board of directors, June 2001 and by the ERS Executive Committee, June 2001. Am. J. Respir. Crit. Care Med. 165(2), 277\u2013304 (2002).","DOI":"10.1164\/ajrccm.165.2.ats01"},{"issue":"Suppl 5","key":"4259_CR26","first-page":"v1","volume":"63","author":"B Bradley","year":"2008","unstructured":"Bradley, B. et al. Interstitial lung disease guideline: the British Thoracic Society in collaboration with the Thoracic Society of Australia and New Zealand and the Irish Thoracic Society. Thorax 63(Suppl 5), v1-58 (2008).","journal-title":"Thorax"},{"key":"4259_CR27","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.745233","volume":"12","author":"T Zhang","year":"2021","unstructured":"Zhang, T. et al. KL-6 as an immunological biomarker predicts the severity, progression, acute exacerbation, and poor outcomes of interstitial lung disease: a systematic review and meta-analysis. Front. Immunol. 12, 745233 (2021).","journal-title":"Front. Immunol."},{"key":"4259_CR28","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/j.rmed.2017.10.020","volume":"132","author":"H Yura","year":"2017","unstructured":"Yura, H. et al. Clinical characteristics of patients with anti-aminoacyl-tRNA synthetase antibody positive idiopathic interstitial pneumonia. Respir. Med. 132, 189\u2013194 (2017).","journal-title":"Respir. Med."},{"issue":"1","key":"4259_CR29","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1186\/s13075-019-1835-9","volume":"21","author":"JS Lee","year":"2019","unstructured":"Lee, J. S. et al. Serum KL-6 levels reflect the severity of interstitial lung disease associated with connective tissue disease. Arthritis Res. Ther. 21(1), 58 (2019).","journal-title":"Arthritis Res. Ther."},{"issue":"7","key":"4259_CR30","doi-asserted-by":"publisher","first-page":"1212","DOI":"10.1093\/rheumatology\/key060","volume":"57","author":"S Sato","year":"2018","unstructured":"Sato, S. et al. Initial predictors of poor survival in myositis-associated interstitial lung disease: a multicentre cohort of 497 patients. Rheumatology (Oxford) 57(7), 1212\u20131221 (2018).","journal-title":"Rheumatology (Oxford)"},{"issue":"3","key":"4259_CR31","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1111\/resp.14609","volume":"29","author":"CJW Stock","year":"2024","unstructured":"Stock, C. J. W. et al. Serum C-reactive protein is associated with earlier mortality across different interstitial lung diseases. Respirology 29(3), 228\u2013234 (2024).","journal-title":"Respirology"},{"issue":"3","key":"4259_CR32","doi-asserted-by":"publisher","first-page":"389","DOI":"10.3346\/jkms.2016.31.3.389","volume":"31","author":"DJ Go","year":"2016","unstructured":"Go, D. J. et al. Elevated erythrocyte sedimentation rate is predictive of interstitial lung disease and mortality in dermatomyositis: a Korean retrospective cohort study. J. Korean Med. Sci. 31(3), 389\u2013396 (2016).","journal-title":"J. Korean Med. Sci."},{"issue":"5","key":"4259_CR33","doi-asserted-by":"publisher","first-page":"361","DOI":"10.2169\/internalmedicine.49.2889","volume":"49","author":"Y Koreeda","year":"2010","unstructured":"Koreeda, Y. et al. Clinical and pathological findings of interstitial lung disease patients with anti-aminoacyl-tRNA synthetase autoantibodies. Intern. Med. 49(5), 361\u2013369 (2010).","journal-title":"Intern. Med."},{"issue":"8","key":"4259_CR34","doi-asserted-by":"publisher","first-page":"1421","DOI":"10.1016\/j.ejrad.2016.05.012","volume":"85","author":"Y Waseda","year":"2016","unstructured":"Waseda, Y. et al. Antisynthetase syndrome: Pulmonary computed tomography findings of adult patients with antibodies to aminoacyl-tRNA synthetases. Eur. J. Radiol. 85(8), 1421\u20131426 (2016).","journal-title":"Eur. J. Radiol."},{"issue":"11","key":"4259_CR35","doi-asserted-by":"publisher","first-page":"1719","DOI":"10.1016\/j.rmed.2009.05.001","volume":"103","author":"A Fischer","year":"2009","unstructured":"Fischer, A. et al. Anti-synthetase syndrome in ANA and anti-Jo-1 negative patients presenting with idiopathic interstitial pneumonia. Respir. Med. 103(11), 1719\u20131724 (2009).","journal-title":"Respir. Med."},{"issue":"1","key":"4259_CR36","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1007\/s11604-020-01030-3","volume":"39","author":"E Baratella","year":"2021","unstructured":"Baratella, E. et al. Interstitial lung disease in patients with antisynthetase syndrome: a retrospective case series study. Jpn. J. Radiol. 39(1), 40\u201346 (2021).","journal-title":"Jpn. J. Radiol."},{"key":"4259_CR37","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.rmed.2017.04.007","volume":"127","author":"K Tanizawa","year":"2017","unstructured":"Tanizawa, K. et al. The long-term outcome of interstitial lung disease with anti-aminoacyl-tRNA synthetase antibodies. Respir. Med. 127, 57\u201364 (2017).","journal-title":"Respir. Med."},{"issue":"5","key":"4259_CR38","doi-asserted-by":"publisher","first-page":"2200425","DOI":"10.1183\/13993003.00425-2022","volume":"60","author":"DA Korevaar","year":"2022","unstructured":"Korevaar, D. A. et al. European Respiratory Society guidelines on transbronchial lung cryobiopsy in the diagnosis of interstitial lung diseases. Eur. Respir. J. 60(5), 2200425 (2022).","journal-title":"Eur. Respir. J."},{"issue":"8","key":"4259_CR39","doi-asserted-by":"publisher","first-page":"1070","DOI":"10.1002\/acr.25347","volume":"76","author":"SR Johnson","year":"2024","unstructured":"Johnson, S. R. et al. 2023 American College of Rheumatology (ACR)\/American College of Chest Physicians (CHEST) Guideline for the Screening and Monitoring of Interstitial Lung Disease in People with Systemic Autoimmune Rheumatic Diseases. Arthritis Care Res. (Hoboken). 76(8), 1070\u20131082 (2024).","journal-title":"Arthritis Care Res. (Hoboken)."},{"issue":"18","key":"4259_CR40","doi-asserted-by":"publisher","first-page":"1718","DOI":"10.1056\/NEJMoa1908681","volume":"381","author":"KR Flaherty","year":"2019","unstructured":"Flaherty, K. R. et al. Nintedanib in progressive fibrosing interstitial lung diseases. N. Engl. J. Med. 381(18), 1718\u20131727 (2019).","journal-title":"N. Engl. J. Med."},{"issue":"6","key":"4259_CR41","doi-asserted-by":"publisher","first-page":"2202071","DOI":"10.1183\/13993003.02071-2022","volume":"61","author":"J Mankikian","year":"2023","unstructured":"Mankikian, J. et al. Rituximab and mycophenolate mofetil combination in patients with interstitial lung disease (EVER-ILD): a double-blind, randomised, placebo-controlled trial. Eur. Respir. J. 61(6), 2202071 (2023).","journal-title":"Eur. Respir. J."},{"issue":"1","key":"4259_CR42","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/S2213-2600(22)00359-9","volume":"11","author":"TM Maher","year":"2023","unstructured":"Maher, T. M. et al. Rituximab versus intravenous cyclophosphamide in patients with connective tissue disease-associated interstitial lung disease in the UK (RECITAL): a double-blind, double-dummy, randomised, controlled, phase 2b trial. Lancet Respir. Med. 11(1), 45\u201354 (2023).","journal-title":"Lancet Respir. Med."},{"issue":"8","key":"4259_CR43","doi-asserted-by":"publisher","first-page":"1182","DOI":"10.1002\/art.42861","volume":"76","author":"SR Johnson","year":"2024","unstructured":"Johnson, S. R. et al. 2023 American College of Rheumatology (ACR)\/American College of Chest Physicians (CHEST) guideline for the treatment of interstitial lung disease in people with systemic autoimmune rheumatic diseases. Arthritis Rheumatol. 76(8), 1182\u20131200 (2024).","journal-title":"Arthritis Rheumatol."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-04259-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-04259-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-04259-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,3]],"date-time":"2025-06-03T11:02:49Z","timestamp":1748948569000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-04259-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,3]]},"references-count":43,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["4259"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-04259-y","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,3]]},"assertion":[{"value":"2 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 June 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This study was approved by the Institutional Review Board of Kanagawa Cardiovascular and Respiratory Center (Approved Number: KCRC-19-0008).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Statements of institutional review board approval"}}],"article-number":"19415"}}